Clinical Edge Journal Scan

Clinical Edge Journal Scan

Commentary: Factors in Psoriatic Arthritis Development and Treatment Response, June 2022

Author:

Vinod Chandran, MBBS, MD, DM, PhD

• Read More

Clinical Edge Journal Scan

IL-22 may serve as a biomarker of response to TNFi and IL-17i in PsA

• Read More

Clinical Edge Journal Scan

Secukinumab safe and effective as a first-line biologic for PsA

• Read More

Clinical Edge Journal Scan

Meta-analysis evaluates impact of bDMARD on QoL in PsA

• Read More

Clinical Edge Journal Scan

PsA: Baseline disease activity predicts achievement of treatment targets with apremilast

• Read More

Clinical Edge Journal Scan

Meta-analysis evaluates degree of skin involvement in patients with PsA vs only psoriasis

• Read More

Clinical Edge Journal Scan

Osteophytes are the most common lesions in PsA patients receiving bDMARD

• Read More

Clinical Edge Journal Scan

Site of infection linked to PsA onset regardless of pathogen

• Read More

Clinical Edge Journal Scan

PsA: Real-world efficacy, safety, and retention rate of secukinumab

• Read More

Clinical Edge Journal Scan

Sex and BMI affect response to systemic PsA therapy

• Read More